Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-tumoral Mitazalimab With IRE in Locally Advanced Pancreas Cancer
NCT06205849Phase 1Recruiting
- Sponsor
- University of California, San Diego
- Start
- Jul 2024
- Primary completion
- Aug 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitazalimab in pancreatic cancer (PC), sponsored by University of California, San Diego. Primary endpoint: Safety and tolerability at 12 weeks. Started Jul 2024; status: recruiting.
02
Drugs
mitazalimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06205849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205849.